If the immune balance cannot be regulated, suppression of excessive immunity will lead to autoimmune diseases, and the treatment of some diseases also needs to suppress the autoimmune function, such as organ transplantation. CD BioSciences is committed to providing comprehensive peptidomimetic development services with immunosuppressive activity to help global customers make greater progress in basic research and pharmaceutical aspects of immune related diseases.
Overview of the Immune System
The immune system is responsible for the detection and removal of foreign pathogens and tumors, and plays an important role in fighting infection and inflammation. The immune system is therefore constantly under surveillance to control and maintain homeostasis. But sometimes an overreaction of immune tools can lead to allergies and autoimmune diseases. About 80-100 different autoimmune diseases have been identified, such as rheumatoid arthritis, Graves' disease, type 1 diabetes, etc. In addition, because the mature host immune system tends to reject foreign organs, resulting in organ transplantation failure, in this case, immunosuppression, that is, targeted reduction of the efficacy of the immune system, is necessary to perform organ transplantation.
Fig. 1 Sites of action of various immunosuppressive drugs. (Sam, et al., 2022)
Disadvantages of Existing Immunosuppressive Drugs
Many immunosuppressants have been used to treat autoimmune diseases, allergies and asthma, and after organ transplantation. Some of these drugs interfere with gene expression, inhibit nucleotide base synthesis to block the cell cycle or target specific kinases. These molecular targets have the disadvantage of affecting the entire immune system, resulting in severe therapeutic and non-therapeutic toxicities such as cardiotoxicity, nephrotoxicity, and post-transplant diabetes.
Benefits of Immunosuppressive Peptides
Therapeutic peptides have attracted widespread attention due to their inherent molecular targeting, which shows less cytotoxicity, high efficacy, and high specificity. A large number of peptides have been studied for their ability to suppress the immune system and are promising immunosuppressive therapeutic entities due to their oral administration properties and remarkable stability.
On this basis, the development of a new generation of peptidomimetics is expected to further optimize the properties of immunosuppressive peptides and promote the research and discovery of new immunosuppressive therapeutic drugs.
Our Services
CD BioSciences provides comprehensive peptidomimetic development services with immunosuppressant activity.
De novo Development Service of Peptidomimetics
Our advanced PepDomTM has high-throughput screening capability. By establishing a high-capacity nucleic acid library and peptide library, it can meet the peptidomimetic development needs of any immunosuppressive site of interest to customers.
Optimization Service of Immunosuppressive Peptides
Whether based on natural or synthetic immunosuppressive peptides, we can develop corresponding peptidomimetics based on our PepDomTM platform to meet the specific requirements of customers for functional characteristics, such as high stability, high permeability and low toxicity, etc.
Features of Our Services
|
Resistance screening to increase oral administration characteristics.
|
|
Special sequence design to achieve accurate targeting.
|
|
Structural optimization to achieve high transmembrane capacity.
|
|
Unique technical modification to reduce toxic and side effects.
|
CD BioSciences focuses on developing peptidomimetics with immunosuppressant activity. As long as you provide the objectives and research directions you are interested in, our professional team will immediately provide you with professional solutions and measures. Welcome to contact us for the best solution.
References
- Sam, K., Andreas, K., & Duvuru, G. (2022). Principles of Immunosuppression in the Management of Kidney Disease: Core Curriculum 2022. American Journal of Kidney Diseases, 0272-6386.
- Usmani, S. S., Agrawal, P., Sehgal, M., Patel, P. K., & Raghava, G. P. S. (2019). ImmunoSPdb: an archive of immunosuppressive peptides. Database, 2019, 1-9.
- Thell, K., Hellinger, R., Schabbauer, G., & Gruber, C. W. (2014). Immunosuppressive peptides and their therapeutic applications. Drug Discovery Today, 19(5), 645–653.
All of our services are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.
